New daily pill MPB-1734 enters human trials for Hard-to-Treat cancers

NCT ID NCT04643418

Recruiting now Disease control Sponsor: MegaPro Biomedical Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new oral drug called MPB-1734 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, and second, testing that dose in specific tumor types. Researchers will monitor side effects and check whether the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MPB-1734 (also called DMB025), a daily oral drug
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early, first-in-human trial with only 81 participants. The drug may not shrink tumors or could cause serious side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR, UNSPECIFIED, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, UNSPECIFIED, ADULT

Contacts and locations

Locations

Taipei Veterans General Hospital
RECRUITING

Taipei, 112, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.